tbuckley/cabot-search huggingface dataset:
Increased 18F-ALF-NOTA-FAPI and 18F-FDG Uptake in Renal Angiomyolipoma
Authors: Yue-Hong Guo, Min-Fu Yang
Journal: Clinical Nuclear Medicine (2022)

Angiomyolipoma is a common benign tumor in the kidney. Previous publication reported that renal angiomyolipoma had very low to low uptake of 18F-FDG. We report a case of pathologically proven angiomyolipoma in the left kidney with intense 18F-FDG and 18F-ALF-NOTA-FAPI uptake.
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes
Authors: Barry J. Maron, Benjamin D. Levine, Reginald L. Washington, Aaron L. Baggish, Richard J. Kovacs, Martin S. Maron
Journal: Journal of the American College of Cardiology (2015)
Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
Authors: Martha Q. Lacy, Betsy R. LaPlant, Kristina M Laumann, Shaji Kumar, Morie A Gertz, Suzanne R Hayman, Francis Buadi, Angela Dispenzieri, John A. Lust, Prashant Kapoor, Nelson Leung, Stephen J. Russell, David Dingli, Wilson I Gonsalves, Rafael Fonseca, P. Leif Bergsagel, Vivek Roy, Taimur Sher, Sikander Ailawadhi, Asher Chanan-Khan, A. Keith Stewart, Craig B. Reeder, S. Vincent Rajkumar, Joseph R. Mikhael
Journal: Blood (2014)
Hepatitis A Among Persons With Hemophilia Who Received Clotting Factor Concentrate— United States, September-December 1995
Journal: JAMA (1996)

Hepatitis A outbreaks associated with receipt of clotting factor concentrate previously have been recognized in Europe but not in the United States (1-5). During September-November 1995, three cases of hepatitis A in recipients of Alphanate factor VIII concentrate (Alpha Therapeutic Corporation, Los Angeles, California) from lot number AP5014A were reported to CDC. On December 8, the manufacturer voluntarily withdrew Alphanate lot number AP5014A from the market. In addition, one case of hepatitis A in a recipient of AlphaNine S-D factor IX concentrate (Alpha Therapeutic Corporation) has been reported and is under investigation. On January 11, 1996, the manufacturer voluntarily withheld four lots of AlphaNine S-D from further distribution as a precautionary measure. This report describes these four cases, summarizes the status of the investigation of the cases, and provides guidelines for testing and reporting of patients who received these products.
The Authors Reply:
Authors: Andrea Baggiano, Michele Boldrini, Ana Martinez-Naharro, Tushar Kotecha, Aviva Petrie, Tamer Rezk, Maurizio Gritti, Cristina Quarta, Daniel S. Knight, Ashutosh D. Wechalekar, Helen J. Lachmann, Stefano Perlini, Gianluca Pontone, James C. Moon, Peter Kellman, Julian D. Gillmore, Philip N. Hawkins, Marianna Fontana
Journal: JACC. Cardiovascular imaging (2020)
Commentaire de travail de J. M. T. Omloo et al., pp. 464
Journal: Endoscopy (2008)

See also:Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancerEndoscopy 2008; 40(06): 464-471DOI: 10.1055/s-2008-1077302
The optimal arterial oxygenation range in critical care
Authors: Lingzhong Meng, Xu Zhao, Eddy Fan
Journal: European Respiratory Journal (2022)

<b>Maintaining <i>P</i><sub>aO<sub>2</sub></sub> in the 70–150 mmHg range might lead to improved survival, compared to a <i>P</i><sub>aO<sub>2</sub></sub> outside of this range, in critically ill patients receiving oxygen therapy. Different <i>P</i><sub>aO<sub>2</sub></sub> targets in the 70–150 mmHg range might not lead to different outcomes.</b>https://bit.ly/3zTngq6
A Personalized Mass Spectrometry–Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)
Authors: Mariya Liyasova, Zac McDonald, Paul Taylor, Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G. Atenafu, Giovanni Piza, Bin Ma, Donna Reece, Suzanne Trudel
Journal: Clinical Cancer Research (2021)

Abstract Purpose: M-protein is a well-established biomarker used for multiple myeloma monitoring. Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity. Measuring residual levels of M-protein in serum by MS was established as a sensitive assay for disease monitoring. In this study we evaluated the performance of EasyM—a noninvasive, sensitive, MS-based assay for M-protein monitoring. Experimental Design: Twenty-six patients enrolled in MCRN-001 clinical trial of two high-dose alkylating agents as conditioning followed by lenalidomide maintenance were selected for the study. All selected patients achieved complete responses (CR) during treatment, whereas five experienced progressive disease on study. The M-protein of each patient was first sequenced from the diagnostic serum using our de novo protein sequencing platform. The patient-specific M-protein peptides were then measured by targeted MS assay to monitor the response to treatment. Results: The M-protein doubling over 6 months measured by EasyM could predict the relapse in 4 of 5 relapsed patients 2 to 11 months earlier than conventional testing. In 21 disease-free patients, the M-protein was still detectable by EasyM despite normal FLC and MRD negativity. Importantly, of 72 MRD negative samples with CR status, 62 were positive by EasyM. The best sensitivity achieved by EasyM, detecting 0.58 mg/L of M-protein, was 1,000- and 200-fold higher compared with serum protein electrophoresis and immunofixation electrophoresis, respectively. Conclusions: EasyM was demonstrated to be a noninvasive, sensitive assay with superior performance compared with other assays, making it ideal for multiple myeloma monitoring and relapse prediction.
Patient Who Became Acutely Ill after Stopping Anti-HIV Treatment
Journal: Annals of Internal Medicine (2000)

Summaries for Patients19 September 2000Patient Who Became Acutely Ill after Stopping Anti-HIV TreatmentSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-6-200009190-00006 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Antiretroviral (anti-HIV) therapy consists of combinations of drugs that slow the growth of the virus. Two laboratory tests, CD4 cell count and viral load, help to monitor patients' response to anti-HIV treatment. CD4 count is a measure of immune cells; high CD4 counts are better than low ones. The viral load is the amount of the virus's genetic material in a person's blood; the lower the viral load, the better. It is well known that the virus starts multiplying rapidly throughout the body when an HIV-infected person stops ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Recurrence of the Acute HIV Syndrome after Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report.” It is in the 19 September 2000 issue of Annals of Internal Medicine (volume 131, pages 435-438). The authors are JM Kilby, PA Goepfert, AP Miller, JW Gnann Jr., M Sillers, MS Saag, and RP Bucy.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRecurrence of the Acute HIV Syndrome after Interruption of Antiretroviral Therapy in a Patient with Chronic HIV Infection: A Case Report J. Michael Kilby , Paul A. Goepfert , Andrew P. Miller , John W. Gnann Jr. , Michael Sillers , Michael S. Saag , and R. Pat Bucy Metrics 19 September 2000Volume 133, Issue 6Page: I-46KeywordsAntiretroviral therapyBloodHIV infectionsLymph nodesMusclesPainPatientsVaccinesViral loadVomiting ePublished: 19 September 2000 Issue Published: 19 September 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Statins for Prostate Cancer: When and How Much?
Authors: Teemu J. Murtola, Aino Siltari
Journal: Clinical Cancer Research (2021)

Abstract Statins have plausible biological effects against prostate cancer cells and are associated with improved disease-specific mortality. In current randomized placebo-controlled trial, low-dose atorvastatin caused no difference in relapses after radical prostatectomy in Asian men. Future trials should study higher statin doses at later disease stages with survival as the endpoint. See related article by Jeong et al., p. 5004
Table of Contents
Authors: Maija Kiuru, Jennifer Urban, Guannan Zhu, Iryna Rybak, Jessica Terrell, Lihong Qi, John Mcpherson, Ashfaq Marghoob, Katherine Rauen, Mondana Ghias, Andrew Johnston, Allison Kutner, Robert Micheletti, H Dean Hosgood, Steven Cohen, Feng Liu-Smith, Argyrios Ziogas, Mats Lambe, Anna Bergstrom, Anna Johansson, Caroline Weibull, Alexandra Bender, Olive Tang, Raveena Khanna, Sonja Sta¨nder, Sewon Kang, Shawn Kwatra, Nour Kibbi, Yuemei Zhang, David Leffell, Sean Christensen, Ying-Xiu Dai, Ying-Hsuan Tai, Chih-Chiang Chen, Yun-Ting Chang, Tzeng-Ji Chen, Mu-Hong Chen
Journal: Journal of the American Academy of Dermatology (2020)
Feasibility of Training Community Health Workers in the Detection of Oral Cancer
Authors: Vipin Thampi, Roopa Hariprasad, Amrita John, Suzanne Nethan, Kavitha Dhanasekaran, Vipin Kumar, Praveen Birur, J. S. Thakur, Richard Lilford, Nasir M. Rajpoot, Paramjit Gill
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Visual screening for oral cancer has been found to be useful in a large randomized clinical trial in Kerala, India, showing substantial reduction in mortality. To address the shortage of medical personnel in resource-deficient regions, using the services of community health workers has been proposed as a strategy to fill the gap in human resources in health care. <h3>Objective</h3> To assess the feasibility of community health workers in screening and early detection of oral cancer using a mobile application capturing system. <h3>Design, Setting, and Participants</h3> A cross-sectional study using a household sample was conducted in 10 areas of Gautam Budhnagar district, Uttar Pradesh, India, from January 31, 2020, to March 31, 2021, to assess the feasibility of identification of oral lesions by community health workers using a mobile phone application compared with diagnosis by trained dentists in a screening clinic. Men and women aged 30 years or older as well as tobacco users younger than 30 years were eligible for screening. <h3>Interventions</h3> Screening by trained community health workers vs dentists. <h3>Results</h3> A total of 1200 participants were screened by the community health workers during their home visits; of these, 1018 participants (526 [51.7%] men; mean [SD] age, 35 [16] years) were also referred and screened by the dentists a clinic. There was near-perfect agreement (κ = 0.9) between the findings of the community health workers and the dentists in identifying the positive or negative cases with overall sensitivity of 96.69% (95% CI, 94.15%-98.33%) and specificity of identification of 98.69% (95% CI, 97.52%-99.40%). <h3>Conclusions and Relevance</h3> In this cross-sectional study, trained community health workers were able after initial supervision by qualified dentists to perform oral cancer screening programs. These findings suggest that community health workers can perform this screening in resource-constrained settings.
Mental health: time to invest in quality
Authors: None The Lancet
Journal: The Lancet (2020)

The theme of this year's World Mental Health Day, on Oct 10, is increased investment in mental health. Why invest, and why now? The answer is simple. At the best of times, good mental health is needed for a society to thrive. During a pandemic, good mental health is more important than ever. Without a focus on mental health, any response to COVID-19 will be deficient, reducing individual and societal resilience, and impeding social, economic, and cultural recovery.
Acute coronary syndrome is not local vascular accident, but pan-coronary process Takayoshi Ohba, Kyoichi Mizuno, Kouji Seimiya, Masamichi Takano, Shinya Yokoyama, Ryuta Uemura, Shunta Sakai, Yoshiki Kusama, Takeshi Ino, Noritake Hata, Takurou Shinada, Yasuhiro Hiarasawa, Jun Tanabe, Kenichirou Tajika, Hiroyuki Kamon. Cardiovascular Medicine, Chiba Hokusou Hospital, Nippon Medical School, Inba Chiba, Japan
Journal: Journal of the American College of Cardiology (2001)
AGE-RELATED MAXIMUM HEART RATE AMONG ISCHEMIC AND NONISCHEMIC HEART FAILURE PATIENTS RECEIVING BETA-BLOCKADE THERAPY
Authors: Miguel Morita Silva, Guilherme Guimar&atilde;es, Jean M. Roque, Iran S. Teixeira Neto, Fernando Bacal, Edimar Bocchi
Journal: Journal of the American College of Cardiology (2012)
Impact of Galectins in Resistance to Anticancer Therapies
Authors: Pilar Navarro, Neus Martínez-Bosch, Ada G. Blidner, Gabriel A. Rabinovich
Journal: Clinical Cancer Research (2020)

Abstract Galectins are an endogenous family of β-galactoside-binding proteins that play complex and multifaceted roles at various stages of cancer progression, including modulation of tumor cell proliferation, signaling, adhesion, migration, invasion, epithelial–mesenchymal transition, angiogenesis, and immune escape. Recently, galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies. Here, we present an integrated approach to the pleiotropic functions of galectins and discuss their emerging roles with respect to mechanisms of resistance or sensitivity to anticancer therapies. Taken together, these findings suggest that targeting galectins and/or their glycosylated ligands may help to overcome resistance and to increase the clinical efficacy of anticancer strategies.
Reply
Authors: Ignacio J. Amat-Santos, Eric Dumont, Marina Urena, Luis Nombela-Franco, Robert DeLarochellière, Daniel Doyle, Rodrigo Bagur, Jacques Villeneuve, Mélanie Côté, François Philippon, Philippe Pibarot, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2012)
ANKYLOSIS.ARTHROPLASTY-CLINICAL AND EXPERIMENTAL.
Authors: JOHN B. MURPHY
Journal: JAMA (1905)

<h3>Case 8.</h3> Mr. Z.; Bohemian, aged 26; was admitted to Mercy hospital April 19, 1904. <h3>Present Illness.</h3> Patient does not speak English and it was impossible, therefore, to obtain a perfectly accurate history. Through an interpreter he stated that stiffness in the right elbow began to develop about ten years ago, and progressed steadily until the joint was completely ankylosed at a right angle. He stated positively that there was no acute inflammation in the joint at any time, and that he had never injured the elbow. From his statement it would seem that the lesion was from the first an ankylosing arthritis. No other joints were involved and his general health was good. He gave no history of tubercular or of specific trouble. <h3>Examination.</h3> The patient is of medium stature, rather poorly nourished. The right forearm was flexed at a right angle, and
Antagomir‐155 Attenuates Acute Cardiac Rejection Using Ultrasound Targeted Microbubbles Destruction
Authors: Luyang Yi, Yihan Chen, Qiaofeng Jin, Cheng Deng, Ya Wu, Huiling Li, Tianshu Liu, Yuman Li, Yali Yang, Jing Wang, Qing Lv, Li Zhang, Mingxing Xie
Journal: Advanced Healthcare Materials (2021)

Adv. Healthcare Mater. 2020, 9, 2000189 DOI: 10.1002/adhm.202000189 In the original version of this article, the project number 8153000372 of the National Natural Science Foundation of China in the Acknowledgements is incorrect. The correct number is 81530056. The authors apologize for any inconvenience caused.
Call for papers on cystic fibrosis: a collaborative research session featuring the<i>European Respiratory Journal</i>,<i>The Lancet Respiratory Medicine</i>and the<i>Journal of Cystic Fibrosis</i>
Journal: European Respiratory Journal (2019)

For the past four years, a research session at the annual European Cystic Fibrosis Society (ECFS) meeting has been co-hosted by The Lancet Respiratory Medicine and the Journal of Cystic Fibrosis . At the 2020 ECFS meeting in June in Lyon, France, we are pleased to announce that the European Respiratory Journal will join this session for the first time.
Incidence and predictive factors of neoaortic regurgitation after arterial switch operation Roberto Formigari, Alessandro Giardini, Marco Bonvicini, Andrea Donti, Daniela Prandstraller, Gabriele Bronzetti, Carlo Pace, Alessandra Toscano, Luciano Pasquini, Gaetano Gargiulo, Fernando M. Picchio. Pediatric Cardiology and Cardiac Surgery, University of Bologna, Policlinico S. Orsola, Bologna, Italy, - Pediatric Cardiology, Ospedale Bambino Ges�, Rome, Italy
Journal: Journal of the American College of Cardiology (2001)
A MEDICAL CONGRESS ON SHIPBOARD.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease
Authors: Niranjan G. Kotla, Rajbir Singh, Becca V. Baby, Swetha Rasala, Jawad Rasool, Sean O. Hynes, Darrell Martin, Laurence J. Egan, Praveen K. Vemula, Venkatakrishna R. Jala, Yury Rochev, Abhay Pandit
Journal: Biomaterials (2022)

Delivering drugs directly to the inflamed intestinal sites to treat inflammatory bowel disease (IBD), particularly Crohn's and ulcerative colitis, is highly challenging. Recent advances in colitis therapy medications are expanding opportunities for improving local on-site drug availability by minimising the associated systemic side-effects. Drug delivery with targeted carrier systems has shown the potential to increase site-specificity, stability, and therapeutic efficacy. Herein, we report the development of a strong anionic charged inflammation targeted nanocarriers (IT-NCs) loaded with an immunosuppressant model drug. This system showed preferential adhesion on a charge-modified surface in vitro, and in both dextran sulfate sodium (DSS) and TNBS colitis mice in vivo models. IT-NCs showed improved colitis phenotype therapeutic efficacy in both animal models compared to free drug. Furthermore, ex vivo study of colon tissue biopsies from patients with colitis revealed that IT-NCs adhered preferentially to inflamed biopsies compared to normal. Together, our results suggest that IT-NCs have promising therapeutic potential as delivery carriers' in colitis management.
NECROLOGY.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review A Brief Rule to Guide the Common-People of New-England: How to order themselves and theirs in the small pocks, or measels . Publications of The Institute of The History of Medicine, The Johns Hopkins University. Fourth series, Bibliotheca Medica Americana, volume I. Thomas Thacher. 70 pp. Baltimore: The Johns Hopkins Press, 1937. $1.50.
Journal: New England Journal of Medicine (1937)
Reply: High-sensitive cardiac troponin after CPAP in obstructive sleep apnoea
Authors: Mary Sau-Man Ip, Hung-Fat Tse, David Chi-Leung Lam, Macy Mei-Sze Lui
Journal: European Respiratory Journal (2022)

We appreciate the correspondence from D. Monneret regarding the issue of analytical precision for troponin assays in the low range of concentrations, and thus the limitations in the interpretation of small decrements in troponin levels. In our study, serum biomarkers were secondary endpoints [1], and the findings and clinical significance of the lowering of troponin levels in the low range of concentrations certainly warrant further delineation in studies specifically targeting the possibility of subclinical myocardial injury in a group of high cardiovascular risk patients, and correlating any biochemical change with functional tests such as cardiac imaging. Regarding potential lot-to-lot variation of the troponin assay, the study samples were tested in batch assay, and paired pre- and post-CPAP samples were analysed in the same lot. Changes in troponin levels in the low concentration range after treatment of obstructive sleep apnoea warrant further studies and functional correlation <https://bit.ly/3HN9iss>
Estrogen Receptor: A Paradigm for Targeted Therapy
Authors: Senthil Damodaran, Gabriel N. Hortobagyi
Journal: Cancer Research (2021)

Abstract Nearly two-thirds of breast cancers overexpress estrogen receptors, and endocrine therapy is considered the backbone of systemic therapy both in early and advanced settings. While this is now widely recognized in clinical practice, this is the culmination of outstanding contribution of many investigators and patients. Indubitably, estrogen receptor targeting has had the most impact among targeted therapies and has significantly affected patient survival. In this commentary, we revisit a landmark article published in Cancer Research in 1977 by Knight and colleagues, which laid the groundwork for the use of estrogen receptors in prognostication and adjuvant treatment selection, as well as some of the key breakthroughs in estrogen receptor biology that span more than a century. See related article by Knight and colleagues, Cancer Res 1977;37:4669–71